^
CANCER:

Soft Tissue Sarcoma





Show legend
Group by Gene:
Include preclinical:

regorafenib
pazopanib
0
Multi-tyrosine kinase inhibitor
ponatinib
cabozantinib tablet
anlotinib
1
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
pembrolizumab + ipilimumab
temozolomide
2
DNA synthesis inhibitor
dacarbazine
gemcitabine
gemcitabine + dacarbazine
nivolumab
3
PD1 inhibitor
pembrolizumab
camrelizumab
temsirolimus
4
mTOR inhibitor
everolimus
sirolimus
doxorubicin hydrochloride
5
Topoisomerase II inhibitor
epirubicin
pegylated liposomal doxorubicin
crizotinib
6
ALK inhibitor
ceritinib
alectinib
7
Progesterone receptor agonist
megestrol
8
Topoisomerase I inhibitor
irinotecan
topotecan
9
Alkylating agent, DNA inhibitor
trabectedin
10
Bcr-abl tyrosine kinase inhibitor
nilotinib
olverembatinib
PARP inhibitor
11
PARP inhibitor
olaparib
rucaparib
12
CDK4 inhibitor, CDK6 inhibitor
palbociclib
13
EZH2 inhibitor
tazemetostat
SHR-2554
14
PD-L1 inhibitor
atezolizumab
envafolimab
15
XPO1 inhibitor
selinexor
16
Bifunctional alkylating agent
ifosfamide
17
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
ifosfamide + pegylated liposomal doxorubicin
doxorubicin hydrochloride + ifosfamide
18
Bifunctional alkylating agent, Topoisomerase II inhibitor
doxorubicin hydrochloride + ifosfamide
ifosfamide + epirubicin
ifosfamide + epirubicin
19
Bcl2 inhibitor, Tubulin inhibitor
albumin-bound paclitaxel
20
Topoisomerase II inhibitor, RNA synthesis inhibitor
dactinomycin
21
Topoisomerase II inhibitor, DNA inhibitor
etoposide oral
22
VEGFR inhibitor
cediranib
23
TNF inhibitor
thalidomide
24
Proteasome inhibitor
bortezomib
25
PDGFR α antagonist
olaratumab
26
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
methotrexate
27
Mitosis inhibitor
vinorelbine
28
Alkylating agent, Tubulin polymerization inhibitor
cyclophosphamide + vinorelbine tartrate
29
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor, Tubulin inhibitor
methotrexate + vinblastine
30
VEGF-A inhibitor
bevacizumab
31
VEGFR inhibitor, PD1 inhibitor
pembrolizumab + axitinib
sintilimab + fruquintinib
32
Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization inhibitor
doxorubicin hydrochloride + ifosfamide + vincristine
33
Tubulin polymerization inhibitor, DNA synthesis inhibitor
gemcitabine + vinorelbine tartrate
34
Tubulin polymerization inhibitor
vinorelbine tartrate
vincristine
35
HSP90 inhibitor
pimitespib
IPI 493
APG-115
36
MDM2 inhibitor
RAIN-32
HDM201
MK-8242
37
Aromatase inhibitor
Aromatase inhibitor
anastrozole
38
BMI1 inhibitor
BMIi-1
39
DNA topoisomerase inhibitor
L-ANN
40
TCR modulator, NY ESO 1 inhibitor
TAEST16001
TBI-1301
41
PD-L1 inhibitor, PARP inhibitor
avelumab + talazoparib
42
TCR modulator, MAGE-A4 inhibitor
ADP-A2M4
43
mTORC1 inhibitor, mTORC2 inhibitor
CB-228
44
MDM2-p53 antagonist
BI 907828
45
PD1 inhibitor, Multi-tyrosine kinase inhibitor
anlotinib + toripalimab-tpzi
46
MEK inhibitor
binimetinib
trametinib
47
Glutaminase inhibitor
IPN60090
48
PRMT5 inhibitor
MRTX1719
49
Hedgehog cell-signalling pathway inhibitor
vismodegib
50
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
51
RET inhibitor
selpercatinib
52
LSD1 inhibitor
SP2577
53
HER2 inhibitor, γδ TCR modulator
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
54
PIK3CA inhibitor, PI3Kδ inhibitor
copanlisib
55
AKT inhibitor
capivasertib
56
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
57
MEK inhibitor, Multi-tyrosine kinase inhibitor
trametinib + pazopanib
58
DNA synthesis inhibitor, PARP inhibitor
olaparib + temozolomide
59
CD70-targeted antibody-drug conjugate
ARX305
AIM
VAC
60
Chemotherapy
AD
MAID
GT
IE
61
Immunotherapy
Immunotherapy
62
ATR inhibitor, PARP1 inhibitor
ATR inhibitor + PARP1 inhibitor
63
c-MET inhibitor, MEK inhibitor
MEK inhibitor + c-MET inhibitor
64
GnRH agonist
GnRH agonist
65
T-lymphocyte cell therapy
T-lymphocyte cell therapy
66
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
67
IGF-1R inhibitor
IGF-1R inhibitor
68
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
69
PDGFR α inhibitor, c-KIT inhibitor, FLT3 inhibitor
ripretinib
70
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
sunitinib + PLX9486
71
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
72
β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
eribulin mesylate
73
ROS1 inhibitor, ALK inhibitor
lorlatinib
74
Tubulin polymerization inhibitor, Topoisomerase I inhibitor
irinotecan + vincristine
75
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
sorafenib
76
Alkylating agent, Topoisomerase I inhibitor
cyclophosphamide + topotecan
77
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
78
Bifunctional alkylating agent, Topoisomerase II inhibitor, Alkylating agent, Tubulin polymerization inhibitor
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
79
Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
gemcitabine + docetaxel
80
Topoisomerase II inhibitor, Tubulin polymerization inhibitor, RNA synthesis inhibitor
vincristine + dactinomycin
81
Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA inhibitor
carboplatin + etoposide oral
82
Tubulin polymerization inhibitor, DNA synthesis inhibitor, Topoisomerase I inhibitor
temozolomide + irinotecan + vincristine
83
Topoisomerase II inhibitor, Alkylating agent, Tubulin polymerization inhibitor
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
84
THF dehydrogenase inhibitor, Tubulin polymerization inhibitor, Dihydrofolic acid reductase inhibitor
methotrexate + vinorelbine tartrate
85
Topoisomerase II inhibitor, DNA synthesis inhibitor
doxorubicin hydrochloride + dacarbazine
86
Tubulin polymerization promoter, Bcl2 inhibitor
paclitaxel
87
TNFα inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
pomalidomide
88
ALK inhibitor, EGFR inhibitor
brigatinib
89
PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
avapritinib
90
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
91
THF dehydrogenase inhibitor, DNA synthesis inhibitor, Thymidylate synthase inhibitor
cisplatin + pemetrexed
92
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
93
pan-RAF inhibitor, VEGF-A inhibitor, mTOR inhibitor, Multi-tyrosine kinase inhibitor
bevacizumab + sorafenib + temsirolimus
94
GPR20 -targeted antibody-drug conjugate, Topoisomerase I inhibitor
DS-6157
95
PDGFR β inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002
96
MCL1 inhibitor, Bcl2 inhibitor
venetoclax + S63845
97
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, mTOR inhibitor, c-KIT inhibitor
imatinib + everolimus
98
VEGFR inhibitor, PDGFR inhibitor, PD1 inhibitor, c-KIT inhibitor
nivolumab + sunitinib
99
PD1 inhibitor, GM-CSF agonist
nivolumab + talimogene laherparepvec
100
pan-RAF inhibitor, Src kinase inhibitor
BAL3833
101
PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor, WEE1 inhibitor
AZD1775 + avapritinib
102
Tubulin binding agent, Microtubule inhibitor
PM184
103
Proteasome inhibitor, CDK9 inhibitor, P-TEFb inhibitor
carfilzomib + VIP152
bortezomib + VIP152
104
FGFR4 inhibitor
ABSK012
105
FGFR inhibitor, PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib + infigratinib
106
c-KIT-targeted antibody-drug conjugate, Microtubule inhibitor
LOP628
107
CD30-targeted antibody-drug conjugate, ALK inhibitor, Microtubule inhibitor
ceritinib + brentuximab vedotin
crizotinib + brentuximab vedotin
108
β-catenin inhibitor, Microtubule stabilizer, Tubulin polymerization promoter, CBP inhibitor, Microtubule inhibitor
docetaxel + eribulin mesylate
109
Glutamine antagonist, Nerve growth factor inhibitor
DR6MP + JHU395
110
Nerve growth factor inhibitor
DR6MP
111
WEE1 inhibitor
AZD1775
112
DNA synthesis inhibitor, Topoisomerase I inhibitor
temozolomide + irinotecan
113
Alkylating agent
cyclophosphamide
114
CDK9 inhibitor, P-TEFb inhibitor
VIP152
115
Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
cisplatin + ifosfamide + epirubicin
116
HDAC inhibitor
romidepsin
vorinostat
117
HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
entinostat
118
Trk inhibitor
BAY 2731954
119
β-catenin inhibitor, XPO1 inhibitor, CBP inhibitor, Microtubule inhibitor
eribulin mesylate + selinexor
120
Microtubule stabilizer, Tubulin polymerization promoter
docetaxel
121
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PD1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
PD1 inhibitor + chidamide
122
c-KIT inhibitor
IDRX-42
123
ATR inhibitor
BAY 1895344
124
CXCL12 inhibitor, Farnesyl transferase inhibitor, MEK inhibitor
trametinib + tipifarnib
125
MEK inhibitor, IGF-1R inhibitor
trametinib + AMG 479
126
XPO1 inhibitor, CDK9 inhibitor, P-TEFb inhibitor
selinexor + VIP152
127
FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor, MDM2 inhibitor
erdafitinib + RG7388
128
FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
erdafitinib
129
PLK4 inhibitor
CFI-400945
130
CD122 agonist, IL-2 stimulant
NKTR-214
131
MCSP inhibitor
CSPG4.TNK
132
CXCL12 inhibitor, Farnesyl transferase inhibitor
tipifarnib
133
VEGFR inhibitor, HSP90 inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib + IPI 493
No biomarker
ALK translocation
KIT mutation
KIT exon 11 mutation
KIT exon 17 mutation
KIT exon 18 mutation
KIT exon 13 mutation
KIT exon 14 mutation
KIT V654A
KIT positive
KIT expression
KIT exon 17 mutation + KIT exon 18 mutation
KIT exon 11 mutation + KIT exon 17 mutation
KIT N822K
KIT N820Y
KIT V560E
KIT V559_E561del
KIT M552_V555delMYEV
KIT W557_V559>F
KIT W557_V559>C
KIT Y823D
KIT N822Y
KIT D820A
KIT D820G
KIT D820Y
KIT wild-type
KIT W557_V559delinsF
KIT D818Y
KIT exon 9 mutation
KIT P577del + KIT W557Lfs*5 + KIT Y823D
KIT exon 11 W557_K558delins
TMB-H
SDHB deletion
SDHB mutation
PGR positive
PDGFRA D842V
PDGFRA mutation
PDGFRA exon 18 mutation
PDGFRA I843_D846delIMHD
HR positive
ER positive + PGR positive
ER positive
CALB1 underexpression
CALB1 deletion
PD-L1 expression
PD-L1 overexpression
TMB-H + PD-L1 expression
GRM1 overexpression
MDM2 amplification
TP53 wild-type
NTRK3 fusion
SMARCB1 deletion
TP53 mutation
SMARCB1 negative
NTRK3 translocation
MDM2 overexpression
TP53 overexpression
FN1-ALK fusion
BRAF V600E
PIK3CA mutation
HLA-A*02:01 + MAGEA4 expression
HER-2 positive
CDK4 amplification
HER-2 negative
ERCC1 overexpression
CDK4 overexpression
HLA-A*02 + MAGEA4 expression
ERCC1 underexpression
PIK3CA E542K
HER-2 expression
EML4-NTRK3 rearrangement
NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion
CTAG1B expression
ALDH1A1 rs3764435
PALB2 deletion
NTRK2 fusion
EZH2 underexpression
RAD51B deletion
HLA-A*02:01
KIT wild-type + SDHB deletion
PTCH E947T
HRD
BRCA2 mutation
BRCA1 mutation
NTRK1 fusion
ASPSCR1-TFE3 fusion +TMB-H
SDHB mutation + NF1 mutation
MDM2 amplification + TP53 wild-type
HLA-A*02:01 + CTAG1B expression
MYH9-ALK + ALK-WDR43
TNFRSF14 overexpression
DUSP9 underexpression
TERT mutation
PIK3CA wild-type + PTEN wild-type
PTEN mutation + TSC1 mutation
LMNA-NTRK1 fusion
QKI-RAF1 fusion
ATF1 overexpression
YWHAE-ROS1 fusion
KIT positive + CD34 positive + ANO1 positive + ACTA2 positive
RBPMS-MET fusion
YWHAE-JAZF1 fusion
TPM3-NTRK1 fusion
JAK1 overexpression
KIAA1549-BRAF fusion + PTEN deletion
TFG-ROS1 rearrangement
STRN-NTRK2 fusion + CDKN2B Deletion
NF1 mutation
TMB-H + PD-L1 overexpression
CD70 expression
RB1 expression
SDHC mutation
TMEM127 mutation
SRC mutation
APC mutation
MSI-H/dMMR
CTLA4 overexpression
LAG3 overexpression
SECTM1 expression
STC2 expression
CTSG expression
IFIH1 expression
SS18-SSX fusion
TFE3 rearrangement + MET expression
HDAC1 amplification
DEPDC5 deletion
CLDN6 positive
FUS-DDIT3 translocation
RET fusion
AKT1 mutation + mTOR mutation
MAD2L2 underexpression
XRCC2 underexpression
RAD54L underexpression
BLM underexpression
APEX2 underexpression
ATM overexpression
SLFN11 overexpression
PIK3R1 overexpression
CDKN2A overexpression
MCM4 overexpression
COL1A1-PDGFB fusion
AKT1 E17K
KANK1-NTRK2 fusion
ERC1-ALK fusion
EWSR1-NR4A3 fusion
ERCC5 overexpression
TYMS underexpression
CUL4A overexpression
KIAA1549-BRAF fusion
KRAS G12V
BRCA2 deletion
NF1 mutation
DDR
Chr del(2)(p12)
ETV6-NTRK3 fusion
PDE4DIP-NTRK1 fusion
ALK1 rearrangement
SQSTM1-NTRK1 fusion
RANBP2-ALK fusion
PIK3CA mutation + TERT promoter mutation
MYCN amplification
EWSR1-TFCP2 fusion
RAS mutation
HRAS mutation
ATRX mutation
CD8 positive
GPR20 expression
TSC2 A736V
FGFR1 overexpression
FGFR4 overexpression
PLK4 expression
IGF1R expression
RAD23B overexpression
CSPG4 overexpression
HAT1 overexpression
FGFR4 V550L
NF2 E108X
HMGA1 overexpression
MVP expression
FGF2 elevation
RANBP2-ALK rearrangement + TNFRSF8 expression
Chr amplification(4)(q22.1)
TAF15-NR4A3 fusion
EWSR1-WT1 fusion
MAN1A1-ROS1 rearrangement
CYP3A4 overexpression
CYP3A5 underexpression
PARP1 underexpression
KDM1A overexpression
MDM2 amplification + CDK4 amplification
PAX3-FOXO1 fusion
ABCB1 expression
ABCG2 expression
SUFU mutation
TEKT4 mutation
MSH3 overexpression
Chr amplification(4)(q26)
Chr amplification(20)(p12.2)
Chr amplification(13)(q13.3)
Chr amplification(8)(q22.2)
Chr amplification(8)(q13.2)
Chr del(1)(q44)
Chr del(2)(q14.1)
Chr del(11)(q25)
Chr del(3)(q14.2)
BRAF-MAD1L1 fusion
DCTN1-NTRK1 fusion
TJP1-ROS1 fusion + NF1 mutation